• 1
    Deutsch V.R., Tomer A. Megakaryocyte development and platelet production. Br J Haematol 2006; 134: 453466.
  • 2
    Houwerzijl EJ, Blom NR, Van der Want JJ, Louwes H, Esselink MT, Smit JW, Vellenga E. Increased peripheral platelet destruction and caspase-3-independent programmed cell death of bone marrow megakaryocytes in myelodysplastic patients. Blood 2005; 105: 34729.
  • 3
    Mahaut-Smith MP, Thomas D, Higham AB, Usher-Smith JA, Hussain JF, Martinez-Pinna J, Skepper JN, Mason MJ. Properties of the demarcation membrane system in living rat megakaryocytes. Biophys J 2003; 84: 264654.
  • 4
    Pang L, Weiss MJ, Poncz M. Megakaryocyte biology and related disorders. J Clin Invest 2005; 115: 33328.
  • 5
    Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006; 354: 203445.
  • 6
    Patel SR, Hartwig JH, Italiano JE Jr. The biogenesis of platelets from megakaryocyte proplatelets. J Clin Invest 2005; 115: 334854.
  • 7
    Cupit LD, Schmidt VA, Gnatenko DV, Bahou WF. Expression of protease activated receptor 3 (PAR3) is upregulated by induction of megakaryocyte phenotype in human erythroleukemia (HEL) cells. Exp Hematol 2004; 32: 9919.
  • 8
    Poujol C, Durrieu-Jais C, Larrue B, Nurden AT, Nurden P. Accessibility of abciximab to megakaryocytes and endothelial cells in the bone marrow compartment: studies on a patient receiving antithrombotic therapy. Br J Haematol 1999; 107: 52631.
  • 9
    Ohmori T, Kashiwakura Y, Ishiwata A, Madoiwa S, Mimuro J, Sakata Y. Silencing of a targeted protein in in vivo platelets using a lentiviral vector delivering short hairpin RNA sequence. Arterioscler Thromb Vasc Biol 2007; 27: 226672.
  • 10
    Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 9279.
  • 11
    Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kitner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O’Donnell C, Roger V, Sorlie P, Steinberger J, et al. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2008; 117: e25146.
  • 12
    Brass S. Cardiovascular biology. Platelets and proteases. Nature 2001; 413: p.e267.
  • 13
    Jackson SP, Yap CL, Anderson KE. Phosphoinositide 3-kinases and the regulation of platelet function. Biochem Soc Trans 2004; 32: 38792.
  • 14
    Woulfe D, Jiang H, Morgans A, Monks R, Birnbaum M, Brass LF. Defects in secretion, aggregation, and thrombus formation in platelets from mice lacking Akt2. J Clin Invest 2004; 113: 44150.
  • 15
    Montanez E, Ussar S, Schifferer M, Bösl M, Zent R, Moser M, Faśsler R. Kindlin-2 controls bidirectional signaling of integrins. Genes Dev 2008; 22: 132530.
  • 16
    Ma YQ, Qin J, Wu C, Plow EF. Kindlin-2 (Mig-2): a co-activator of beta3 integrins. J Cell Biol 2008; 181: 43946.
  • 17
    Moser M, Nieswandt B, Ussar S, Pozgajova M, Fässler R. Kindlin-3 is essential for integrin activation and platelet aggregation. Nat Med 2008; 14: 32530.
  • 18
    Chen J, De S, Damron DS, Chen WS, Hay N, Byzova TV. Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice. Blood 2004; 104: 170310.
  • 19
    Li D, August S, Woulfe DS. GSK3beta is a negative regulator of platelet function and thrombosis. Blood 2008; 111: 352230.
  • 20
    Stojanovic A, Marjanovic JA, Brovkovych VM, Peng X, Hay N, Skidgel RA, Du X. A phosphoinositide 3-kinase-AKT-nitric oxide-cGMP signaling pathway in stimulating platelet secretion and aggregation. J Biol Chem 2006; 281: 163339.
  • 21
    Zhang W, Colman RW. Thrombin regulates intracellular cyclic AMP concentration in human platelets through phosphorylation/activation of phosphodiesterase 3A. Blood 2007; 110: 147582.
  • 22
    Bertoni A, Tadokoro S, Eto K, Pampori N, Parise LV, White GC, Shattil SJ. Relationships between Rap1b, affinity modulation of integrin alpha IIbbeta 3, and the actin cytoskeleton. J Biol Chem 2002; 277: 2571521.
  • 23
    Tadokoro S, Shattil SJ, Eko K, Tai V, Liddington RC, De Pereda JM, Ginsberg MH, Calderwood DA. Talin binding to integrin beta tails: a final common step in integrin activation. Science 2003; 302: 1036.
  • 24
    Han J, Lim CJ, Watanabe N, Soriani A, Ratnikov B, Calderwood DA, Puzon-McLaughlin W, Lafuente EM, Boussiotis VA, Shattil SJ, Ginsberg MH. Reconstructing and deconstructing agonist-induced activation of integrin alphaIIbbeta3. Curr Biol 2006; 16: 1796806.
  • 25
    Covic L, Misra M, Badar J, Singh C, Kuliopulos A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 2002; 8: 11615.
  • 26
    Chackalamannil S, Xia Y, Greenlee WJ, Clasby M, Doller D, Tsai H, Asberom T, Czarniecki M, Ahn HS, Boykow G, Foster C, Agans-Fantuzzi J, Bryant M, Lau J, Chintala M. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J Med Chem 2005; 48: 58847.
  • 27
    Chackalamannil S, Wang Y, Greenlee WJ, Hu Z, Xia Y, Ahn HS, Boykow G, Hsieh Y, Palamanda J, Agans-Fantuzzi J, Kurowski S, Graziano M, Chintala M. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem 2008; 51: 30614.
  • 28
    Becker R, Moliterno DJ, Jennings LK, Pieper K, Pei J, Niederman A, Ziada K, Berman G, Strony J, Joseph D, Mahaffey KW, Van der Werf F, Veltri E, Harrington R. Safety and tolerability of SCH-530348 in patients undergoing non-urgenty percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373: 91928.
  • 29
    Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, Roe MT, Kuliopulos A, Moliterno DJ, French PA, Steinhubl SR, Becher RC. G-Protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol (ATVBAHA) 2009; 29: 44957.
  • 30
    Kogushi M, et al. Effects of E5555, A protease-activated receptor-1 antagonist, on the inflammatory markers in vitro. Abstract number: P-M-059. J Thromb Haemost 2007; 5(Suppl. 1). August.
  • 31
    Wodnicka MB, et al. Bleeding phenotype and decreased viability in Rap1b knockout mice. J Thromb Haemost 2003; 1(Suppl.): OC213.
  • 32
    Lova P, Paganini S, Sinigaglia F, Balduini C, Torti M. A Gi-dependent pathway is required for activation of the small GTPase Rap1B in human platelets. J Biol Chem 2002; 277: 1200915.
  • 33
    Petrich BG, Fogelstrand P, Partridge AW, Yousefi N, Ablooglu AJ, Shattil SJ, Ginsberg MH. The antithrombotic potential of selective blockade of talin-dependent integrin alpha IIb beta 3 (platelet GPIIb-IIIa) activation. J Clin Invest 2007; 117: 22509.
  • 34
    Hansson GK, Libby P, Schönbeck U, Yan ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002; 91: 28191.
  • 35
    Yamashita A, Asada Y, Sugimura H, Yamamoto H, Marutsuka K, Hatakeyama , Tamura S, Ikeda Y, Sumiyoshi A. Contribution of von Willebrand factor to thrombus formation on neointima of rabbit stenotic iliac artery under high blood-flow velocity. Arterioscler Thromb Vasc Biol 2003; 23: 110510.
  • 36
    Oney S, Nimjee SM, Layzer J, Que-Gewirth N, Ginsburg D, Becker RC, Arepally G, Sullenger BA. Antidote-controlled platelet inhibition targeting Von Willebrand factor with aptamers. Oligonucleotides 2007; 17: 265274.